Nathalie Castéran

Masitinib (AB1010), a Potent and Selective Tyrosine Kinase Inhibitor Targeting KIT

Patrice Dubreuil, Sébastien Letard, Marco A. Ciufolini et al. · PLoS ONE · 2009 · 404 citations · Full text

Effect of tyrosine kinase inhibitor STI571 on the kinase activity of wild-type and various mutated c-kit receptors found in mast cell neoplasms

Yaël Zermati, Paulo De Sepulveda, Frédéric Féger et al. · Oncogene · 2003 · 188 citations

Signal Transduction, Signaling Pathway, Mast Cell Disorder +8

Substrate specificities and identification of a putative binding site for PI3K in the carboxy tail of the murine Flt3 receptor tyrosine kinase.

Robert Rottapel, C W Turck, Nathalie Castéran et al. · PubMed · 1994 · 75 citations

Masitinib Combined with Standard Gemcitabine Chemotherapy: In Vitro and In Vivo Studies in Human Pancreatic Tumour Cell Lines and Ectopic Mouse Model

Martine Humbert, Nathalie Castéran, Sébastien Letard et al. · PLoS ONE · 2010 · 74 citations · Full text

Signal transduction by several KIT juxtamembrane domain mutations

Nathalie Castéran, Paulo De Sepulveda, Nathalie Beslu et al. · Oncogene · 2003 · 68 citations

Molecular Physiology, Signal Transduction, Natural Sciences +5